PL2726470T3 - Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych - Google Patents

Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych

Info

Publication number
PL2726470T3
PL2726470T3 PL12737238T PL12737238T PL2726470T3 PL 2726470 T3 PL2726470 T3 PL 2726470T3 PL 12737238 T PL12737238 T PL 12737238T PL 12737238 T PL12737238 T PL 12737238T PL 2726470 T3 PL2726470 T3 PL 2726470T3
Authority
PL
Poland
Prior art keywords
thiadiazol
treatment
neurodegenerative diseases
derivatives useful
ylpiperazine
Prior art date
Application number
PL12737238T
Other languages
English (en)
Inventor
Gerard Griffioen
Matthias Nettekoven
Katrien Princen
Hasane Ratni
Walter Vifian
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv filed Critical Remynd Nv
Publication of PL2726470T3 publication Critical patent/PL2726470T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PL12737238T 2011-07-01 2012-06-29 Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych PL2726470T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11172324 2011-07-01
EP20120737238 EP2726470B1 (en) 2011-07-01 2012-06-29 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
PCT/EP2012/062778 WO2013004642A1 (en) 2011-07-01 2012-06-29 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases

Publications (1)

Publication Number Publication Date
PL2726470T3 true PL2726470T3 (pl) 2015-09-30

Family

ID=46545347

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12737238T PL2726470T3 (pl) 2011-07-01 2012-06-29 Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych

Country Status (9)

Country Link
US (1) US9023852B2 (pl)
EP (1) EP2726470B1 (pl)
JP (1) JP5972367B2 (pl)
CN (1) CN103619825B (pl)
AU (1) AU2012280420B2 (pl)
CA (1) CA2837247C (pl)
ES (1) ES2540956T3 (pl)
PL (1) PL2726470T3 (pl)
WO (1) WO2013004642A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296804B2 (en) * 2011-08-17 2017-04-20 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
EP3119774A1 (en) * 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
WO2017223474A1 (en) * 2016-06-23 2017-12-28 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
JP2019533022A (ja) * 2016-10-24 2019-11-14 ユマニティ セラピューティクス,インコーポレーテッド 化合物及びその使用
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
JP7527967B2 (ja) 2017-12-27 2024-08-05 セント ジュード チルドレンズ リサーチ ホスピタル,インコーポレイティド Castorに関連する障害を治療する方法
MX2020006754A (es) 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
CA3094527A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2025104092A1 (en) 2023-11-13 2025-05-22 Remynd N.V. Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220422T3 (es) * 1999-03-03 2004-12-16 Wyeth Nuevos derivados de diazol como agentes serotonergicos.
WO2000064885A1 (en) * 1999-04-26 2000-11-02 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine
PE20070099A1 (es) * 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
US7632838B2 (en) * 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases

Also Published As

Publication number Publication date
JP5972367B2 (ja) 2016-08-17
EP2726470A1 (en) 2014-05-07
HK1192726A1 (en) 2014-08-29
US9023852B2 (en) 2015-05-05
JP2014518240A (ja) 2014-07-28
CA2837247A1 (en) 2013-01-10
CN103619825A (zh) 2014-03-05
WO2013004642A1 (en) 2013-01-10
US20140128404A1 (en) 2014-05-08
EP2726470B1 (en) 2015-04-29
ES2540956T3 (es) 2015-07-15
CN103619825B (zh) 2015-10-14
CA2837247C (en) 2020-03-31
AU2012280420A1 (en) 2013-12-12
AU2012280420B2 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
SMT201700531T1 (it) Derivati estrogeni per uso nel trattamento di disordini neurologici
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
ZA201308176B (en) Therapeutic treatment
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
PL395175A1 (pl) Nowe pochodne dekstrometorfanu i sposób ich wytwarzania